In vivo最新文献

{"title":"The Hemoglobin, Albumin, Lymphocyte and Platelet (HALP) Score as an Independent Prognostic Factor for Esophageal Cancer Patients who Received Curative Treatment.","authors":"Sosuke Yamamoto, Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Ryuki Esashi, Keisuke Kazama, Jyunya Morita, Shinnosuke Kawahara, Mamoru Uchiyama, Koji Numata, Kiyoko Shimada, Ayako Tamagawa, Aya Saito, Norio Yukawa","doi":"10.21873/invivo.13892","DOIUrl":"10.21873/invivo.13892","url":null,"abstract":"<p><strong>Background/aim: </strong>Esophageal cancer (EC) is a malignant tumor with poor prognosis. Prognostic factors that may be used in the treatment and management of EC are important. The purpose of this study was to evaluate the impact of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score on the long-term oncological prognosis of patients with EC who have undergone curative treatment.</p><p><strong>Patients and methods: </strong>Patients with EC who underwent curative resection at Yokohama City University between 2000 and 2020 were included. Clinical data were retrospectively retrieved from medical records and analyzed. The HALP score was determined as follows: HALP=[hemoglobin (g/l)×albumin (g/l)×lymphocytes (/l)]/platelets (/l). Kaplan-Meier method and Cox regression model were used to assess the overall (OS) and recurrence-free survival (RFS) and to evaluate the prognostic value of the HALP score.</p><p><strong>Results: </strong>In total, 180 patients were included in this study. They were classified into the HALP-low (n=110) and HALP-high (n=70) groups using a cutoff value of 40. The 5-year OS rate was 46.9% in the HALP-low group and 66.0% in the HALP-high group (<i>p</i>=0.012). The 5-year RFS rate was 31.1% in the HALP-low group and 51.4% in the HALP-high group (<i>p</i>=0.006). The HALP score was found to be an independent prognostic factor for OS [odds ratio (OR)=1.954, 95% confidence interval (CI)=1.157-3.299, <i>p</i>=0.012] and RFS (OR=1.852, 95% CI=1.197-2.866, <i>p</i>=0.006).</p><p><strong>Conclusion: </strong>The HALP score is a factor that predicts the oncological prognosis in patients with EC who have undergone radical resection.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"885-893"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Hydrogen Therapy for SLE-PAH: Case Report on Immune Marker Modulation.","authors":"Ting-Hao Tu, Jeng-Wei Lu, Chun-Hsien Wu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu","doi":"10.21873/invivo.13926","DOIUrl":"10.21873/invivo.13926","url":null,"abstract":"<p><strong>Background/aim: </strong>Systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH) is a severe complication marked by elevated pulmonary artery pressure, leading to exertional dyspnea and right-sided heart failure. Standard treatments frequently fall short in effectively controlling symptoms, highlighting the need for innovative therapeutic approaches. This aim of this study was to investigate the efficacy of molecular hydrogen therapy in a patient with SLE-PAH with decompensated right-side heart failure.</p><p><strong>Case report: </strong>We present the case of a 51-year-old female diagnosed with SLE-PAH in 2012. Despite treatment with vasodilator agents, her condition worsened following an episode of sepsis, leading to severe dyspnea and oxygen desaturation since 2018. In March 2024, molecular hydrogen therapy was introduced as an adjuvant treatment. The patient received daily hydrogen capsules, which resulted in an increased percentage of Tr1 cells, and a decreased percentage of Treg cell subsets, B cell subsets, marginal cell, and plasma cell. Her clinical symptoms stabilized, and no adverse effects or complications were observed.</p><p><strong>Conclusion: </strong>This case study highlights the potential efficacy of molecular hydrogen therapy in a patient with SLE-PAD and decompensated right-sided heart failure precipitated by sepsis. Further research is needed to confirm its therapeutic benefits, particularly its ability to modulate immune markers and improve clinical outcomes.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1211-1219"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardized <i>Pluchea Indica</i> Leaf Extract Exhibited Antiproliferative Activity Against TGF-β-induced Prostate Stromal Cells (WPMY-1) Through G 1 Phase Cell Cycle Arrest <i>via</i> SMAD2/3 and ERK1/2 Signaling Pathways.","authors":"Yanisa Kanphet, Tamonwan Uttarawichien, Boonyadist Vongsak, Teerawat Boonsom, Nonthaneth Nalinratana, Sathiyaraj Sivaji, Pasarapa Towiwat, Suchada Sukrong","doi":"10.21873/invivo.13882","DOIUrl":"10.21873/invivo.13882","url":null,"abstract":"<p><strong>Background/aim: </strong>Benign prostatic hyperplasia (BPH) is characterized by the abnormal proliferation of prostate stromal cells, resulting in the enlargement of the prostate gland and the manifestation of troublesome symptoms, such as nocturia, urinary retention, and urinary incontinence. Dihydrotestosterone (DHT) and interleukin-17 (IL-17) are known to be key factors in promoting the overproduction of transforming growth factor-beta (TGF-β) in prostate stromal cells, contributing to their excessive proliferation, leading to BPH.</p><p><strong>Materials and methods: </strong>In this study, selected plant extracts traditionally used to alleviate urinary symptoms were subjected to primary screening for their anti-proliferative activity by evaluating DHT- and IL-17-induced proliferation in WPMY-1 prostate stromal cells. This was followed by a secondary screening using TGF-β induction.</p><p><strong>Results: </strong>The extract that significantly inhibited cell proliferation was standardized and further investigated for its anti-proliferative effects through the TGF-β signaling pathway. Results showed that the leaf extract of <i>P. indica</i> significantly inhibited cell proliferation induced by DHT, IL-17, and TGF-β. It was demonstrated that <i>P. indica</i> has anti-proliferative properties <i>via</i> the TGF-β signaling pathways by inhibiting PCNA protein expression and inducing cell accumulation at the G₀/G₁ phase, while reducing the cell population at the S phase. Additionally, it down-regulated the expression of both canonical (p-SMAD2/3) and non-canonical (p-ERK1/2) proteins in TGF-β-induced WPMY-1 cells.</p><p><strong>Conclusion: </strong>The standardized leaf extract of <i>P. indica</i> showed notable anti-proliferative activity against TGF-β-induced WPMY-1 cells by arresting the cell cycle at the G₀/G₁ phase through the SMAD2/3 and ERK1/2 signaling pathways.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"778-794"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraoperative Aberrometer Plus Image-guided System for Astigmatism Correction Compared to Standard Image-guided System for Significant Lens Opacity.","authors":"Michael Chia-Yen Chou, Chia-Yi Lee, Shun-Fa Yang, Yu-Hsu Chen, Hung-Yu Lin","doi":"10.21873/invivo.13908","DOIUrl":"10.21873/invivo.13908","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to evaluate astigmatism after cataract surgery by comparing the use of an intraoperative aberrometer combined with an image-guided system (VLynk) <i>versus</i> an image-guided system alone (Verion) in patients with significant lens opacity.</p><p><strong>Patients and methods: </strong>The main outcomes included the corrected distance visual acuity (CDVA), astigmatism, spherical equivalent (SE) status, and the predicting factors for reduced astigmatism in the two groups.</p><p><strong>Results: </strong>In this study, 73 patients were enrolled in the study group (VLynk); 76 individuals constituted the control group (Verion). Preoperative and postoperative CDVA between both groups were similar (all <i>p</i>>0.05). The postoperative cylinder power (<i>p</i>=0.002), postoperative SE (<i>p</i>=0.004), and the difference between real SE and estimated SE (<i>p</i>=0.001) were significantly lower in the VLynk group. Implantation of toric IOL was associated with less astigmatism in both groups (both <i>p</i><0.05). Longer axial length (<i>p</i>=0.013) and higher central corneal power (<i>p</i>=0.023) were correlated with greater astigmatism in the Verion group.</p><p><strong>Conclusion: </strong>VLynk is correlated with better postoperative astigmatism control and predictability compared to Verion in patients with significant lens opacity.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1033-1041"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of High-positioning Pelvic Pads in Laparoscopic Sigmoid Colon and Rectal Surgeries.","authors":"Masato Kitazawa, Satoshi Nakamura, Yuta Yamamoto, Satoru Miyazaki, Nao Hondo, Masahiro Kataoka, Hirokazu Tanaka, Yuji Soejima","doi":"10.21873/invivo.13912","DOIUrl":"10.21873/invivo.13912","url":null,"abstract":"<p><strong>Background/aim: </strong>The increased use of robotic rectal surgery has raised concerns regarding the increase in postoperative complications, <i>e.g.</i>, compartment syndrome, associated with factors such as the Trendelenburg position, use of the adjustable lithotomy stirrup, and prolonged surgical duration. Therefore, in this study, we evaluated the utility of high-positioning pelvic pads during laparoscopic rectal and sigmoid colon surgeries, which is employed in our institution to maintain a stable body position with reduced head-down tilt.</p><p><strong>Patients and methods: </strong>We included patients who underwent laparoscopic sigmoidectomy and rectal resection at Shinshu University Hospital between January 2016 and December 2021. We performed two studies: Study 1 compared the short-term treatment outcomes between patients who used high-positioning pelvic pads during surgery and those who did not, whereas Study 2 analyzed factors affecting the time to inferior mesenteric artery division using multivariate analysis.</p><p><strong>Results: </strong>In Study 1, no significant differences in patient demographics were observed between the groups. The use of high-positioning pelvic pads significantly reduced the overall surgical time and number of gauzes used, with no significant differences in blood loss, complication rates, or duration of hospital stay. In Study 2, we identified intra-abdominal adhesions requiring adhesiolysis and use of high-positioning pelvic pads as factors influencing the time to inferior mesenteric artery division.</p><p><strong>Conclusion: </strong>The use of high-positioning pelvic pads facilitated surgeries with a reduced head-down tilt, thereby contributing to shorter surgical times. This approach may help decrease the incidence of compartment syndrome, suggesting the need for further prospective trials and studies on robotic surgery.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1078-1085"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New-onset Bipolar Disorder in Hidradenitis Suppurativa Patients: A Multi-center, Propensity-score-matched Cohort Study.","authors":"Meng-Che Wu, Yun-Feng Li, Chen-Yu Lin, Nung-Hsiang Lin, Chien-Ying Lee, Yu-Jung Su, Hui-Chin Chang, Shuo-Yan Gau","doi":"10.21873/invivo.13911","DOIUrl":"10.21873/invivo.13911","url":null,"abstract":"<p><strong>Background/aim: </strong>Hidradenitis suppurativa (HS) may be linked to an elevated risk of bipolar disorder, though the precise mechanism remains unclear. This study investigated the likelihood of bipolar disorder in patients with HS.</p><p><strong>Patients and methods: </strong>We analyzed the electronic health records of 60,850 patients with HS and 60,850 matched controls from the TriNetX network, excluding those with a prior bipolar disorder diagnosis. Propensity score matching was conducted (1:1 ratio), and hazard ratios (HRs) were calculated to assess the risk of new-onset bipolar disorder in patients with HS compared to controls.</p><p><strong>Results: </strong>After matching, the HR for developing bipolar disorder in patients with HS was 1.549 [95% confidence interval (CI)=1.270-1.889] after a 1-year follow-up, remaining significant in 3- and 5-year follow-ups and sensitivity analyses. Stratified by sex, female patients with HS showed a notably higher risk (HR=1.509, 95%CI=1.353-1.683), while no significant increase was seen in males.</p><p><strong>Conclusion: </strong>Patients with HS have a significantly elevated risk of developing bipolar disorder, especially among females. Healthcare providers should be mindful of this association when treating patients with HS.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1067-1077"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis.","authors":"Ece Akbayir, Tugce Kizilay, Ruziye Erol, Duygu Ozkan-Yasargun, Erdem Tuzun, Vuslat Yilmaz, Recai Turkoglu","doi":"10.21873/invivo.13920","DOIUrl":"10.21873/invivo.13920","url":null,"abstract":"<p><strong>Background/aim: </strong>Ocrelizumab, a CD20-targeting monoclonal antibody, is used for treatment of multiple sclerosis. The aim of this study was to explore the utility of peripheral blood cell subsets in prediction of treatment response to ocrelizumab in relapsing remitting multiple sclerosis (RRMS).</p><p><strong>Patients and methods: </strong>Thirty-one patients with RRMS resistant to first-line immunomodulating agents were enrolled and followed-up for 12 months under ocrelizumab treatment. Disease activity was monitored by 6-monthly assessments of Expanded Disability Status Scale and cranial-spinal magnetic resonance imaging. No evidence of disease activity (NEDA-3) status was determined, and peripheral blood mononuclear cells were immunophenotyped by flow cytometry.</p><p><strong>Results: </strong>Peripheral blood populations of CD19⁺ B-cells, plasma cells and CD3⁺ CD20⁺ T-cells decreased under ocrelizumab therapy, whereas populations of switched memory B-cells, CD4⁺ T-cells, naïve T-cells and regulatory B-1a and CD49d⁺ T-cells were increased. NEDA-3 status was achieved by 19 patients, who exhibited elevated baseline populations of regulatory CD49d⁺ T- and B-1a-cells, reduced post-treatment (month 6 or 12) populations of switched memory B-cells, and increased post-treatment populations of naïve T-cells. Month 12 Expanded Disability Status Scale scores correlated positively with plasmablast and naïve T-cell populations.</p><p><strong>Conclusion: </strong>Response to ocrelizumab is linked to baseline regulatory and post-treatment effector B- and T-cell subset populations. Memory B-cells appear to be a marker of treatment efficacy for ocrelizumab.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1162-1172"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Newly Installed Spot Scanning Proton Beam Therapy for Prostate Cancer.","authors":"Sachika Shiraishi, Yukiyasu Horikawa, Ryota Umeda, Kazuki Matsumoto, Akihiro Yamano, Masashi Yamanaka, Takahiro Shimo, Taro Murai, Ichiro Miura, Koichi Tokuuye","doi":"10.21873/invivo.13888","DOIUrl":"10.21873/invivo.13888","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to analyse retrospectively the initial treatment outcomes and associated toxicities of a spot scanning proton beam therapy for prostate cancer at the Shonan-Kamakura General Hospital.</p><p><strong>Patients and methods: </strong>A laterally opposing single-field uniform dose of spot-scanning proton beam was used. The doses were determined to be 60 Gy in 20 fractions for low-risk prostate cancer and 63 Gy in 21 fractions for intermediate- and high-risk prostate cancers. Genitourinary (GU) and gastrointestinal (GI) toxicities were also evaluated. Toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</p><p><strong>Results: </strong>A total of 135 patients were treated over two years, 51 of whom underwent hydrogel spacer insertion. During the limited observation period, no patient experienced a recurrence. Grade 2 GU toxicities were observed in 17 patients, whereas grade 1 or greater GI toxicities were observed in seven patients. None of the patients in whom a hydrogel spacer was inserted experienced grade 1 or higher GI toxicity.</p><p><strong>Conclusion: </strong>Proton beam therapy is safe for the treatment of prostate cancer. The insertion of a gold marker and hydrogel spacer led to a reduction in the rectal radiation dose and GI toxicity.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"851-858"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Hydrogen Therapy Enhances Immune Markers in Treg, Plasma, Tr1 Cells, and KLRG1 Expression on Tc Cells: A Case of Acute SDH With Midline Shift and Uncal Herniation Post-decompressive Craniectomy.","authors":"Hui-Fu Hsu, Ruei-Yang Hu, Jeng-Wei Lu, Dueng-Yuan Hueng, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Hsiao-Chen Liu, Feng-Cheng Liu","doi":"10.21873/invivo.13923","DOIUrl":"10.21873/invivo.13923","url":null,"abstract":"<p><strong>Background/aim: </strong>Subdural hematomas (SDH), often caused by head trauma, are serious with high mortality and long-term complications. Studies show that molecular hydrogen has neuroprotective effects, such as reducing oxidative stress, inflammation, and cell death. It may also protect mitochondria, support cell function, and regulate immune responses, making it a promising new treatment option for SDH. However, more research is needed to confirm its effectiveness and create treatment guidelines.</p><p><strong>Case report: </strong>We present a 24-year-old man with SDH, along with a right-sided midline shift, uncal herniation, and dilated left pupil. Conventional treatments-craniectomy, hyperbaric oxygen, therapeutic hypothermia, and stem cell therapy-were essential for stabilizing his condition. In addition, we administered hydrogen capsules as a novel adjunct therapy, beginning daily treatment immediately upon admission. While recovery was primarily due to standard interventions, hydrogen therapy appeared to enhance immune markers, particularly Treg and plasma cells, with no adverse effects. This case indicates that hydrogen therapy may serve as a beneficial addition to established SDH management methods.</p><p><strong>Conclusion: </strong>This case suggests that molecular hydrogen therapy may be a helpful adjunct treatment for SDH with midline shift. Conventional therapies, including craniectomy, hyperbaric oxygen, therapeutic hypothermia, and stem cell therapy, were vital to the patient's recovery, but hydrogen therapy may have contributed by modulating immune responses, particularly Treg and plasma cell activity. While these findings are encouraging, further research is necessary to confirm hydrogen therapy's benefits and its role alongside traditional neurocritical care treatments.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1190-1199"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing.","authors":"Nobuki Furubayashi, Manabu Mochida, Atsuhiro Kijima, Yushi Fujimoto, Motonobu Nakamura, Takahito Negishi","doi":"10.21873/invivo.13903","DOIUrl":"10.21873/invivo.13903","url":null,"abstract":"<p><strong>Background/aim: </strong>The efficacy and safety of avelumab according to age, performance status (PS), and infusion timing in patients with advanced urothelial carcinoma (UC) are unclear.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed data from patients with advanced UC who received avelumab, without progression to first-line platinum-based chemotherapy. Efficacy and safety were evaluated according to age (<70, ≥70 to <80, and ≥80 years), PS (0 and ≥1), and infusion time of the first dose (early and late).</p><p><strong>Results: </strong>Twenty-three patients were analyzed [age (<70 years, n=10; ≥70 to <80, n=8; ≥80, n=5; PS (PS0, n=20; PS≥1, n=3); timing (early, n=13; late, n=10)]. Rates of any-grade adverse events (AEs) and grade ≥2 AEs were not significantly influenced by age (<i>p</i>=0.748 and <i>p</i>=0.615, respectively), PS (<i>p</i>>0.999 and <i>p</i>=0.539), or timing (<i>p</i>=0.685 and <i>p</i>=0.618). The disease control rate was not significantly influenced by age (<i>p</i>=0.663), PS (<i>p</i>>0.178), or timing (<i>p</i>=0.417). Median progression-free survival (PFS) was not significantly influenced by age (<i>p</i>=0.979), PS (<i>p</i>=0.620), or timing (<i>p</i>=0.208). Median overall survival (OS) was not significantly influenced by age (<i>p</i>=0.354), PS (<i>p</i>=0.590), or timing (<i>p</i>=0.552). When patients were divided into two groups according to PFS ≥6 months, OS was significantly different between the PFS <6 months group and the ≥6 months group (<i>p</i>=0.016).</p><p><strong>Conclusion: </strong>The efficacy and safety of avelumab maintenance therapy was not significantly influenced by age, PS, or infusion timing, and PFS ≥6 months could be a surrogate marker for OS.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"976-987"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}